Abstract:Yueying Niu, 1 Mengqing Cao, 1 Shumin Li, 1 Juanfen Mo, 2 Ziyi Zhu, 1 Haiqin Wang 1 1 Department of Respiratory Medicine, The Second Hospital of Jiaxing, Jiaxing, Zhejiang, People's Republic of China; 2 The Key Laboratory, The Second Hospital of Jiaxing, Jiaxing, Zhejiang, People's Republic of China Correspondence: Haiqin Wang; Ziyi Zhu, Department of Respiratory Medicine, The Second Hospital of Jiaxing, 1518 Huanchen North Road, Jiaxing, Zhejiang, 314000, People's Republic of China, Email ; Objective: To retrospectively study the effects of budesonide inhalation combined with conventional symptomatic treatment on serum inflammatory factor expression levels and pulmonary function in patients with cough variant asthma (CVA) and to evaluate treatment efficacy. Methods: This retrospective cohort study included 200 patients diagnosed with CVA at the Second Hospital of Jiaxing between January 2022 and June 2023 and given conventional symptomatic treatment plus budesonide inhalation were included in this study. Patients were divided into a no remission group, a partial remission group and a complete remission group based on treatment effect. The expression levels of serum inflammatory factors, cough symptom scores, and small airway function indicators in the three groups of patients at different time points were compared. Results: In the three groups of CVA patients, after receiving budesonide inhalation combined with conventional symptomatic treatment, the expression levels of serum IL-5, IL-6, IL-8, TNF-α, TGF-β 1, and IgE and number of eosinophils significantly decreased (P < 0.05). There were statistically significant differences in the IL-6 and TGF-β 1 levels among the three groups of CVA patients at T1, T2 and T3. There were statistically significant differences in IgE levels, number of eosinophils, cough symptom scores, and small airway function indicators between T2 and T3 (P< 0.05). The receiver operating characteristic (ROC) curve prediction analysis revealed significant differences in the expression of IL-6 and TGF-β 1 at T1, T2, and T3. Conclusion: Budesonide inhalation combined with conventional symptomatic treatment can significantly reduce the levels of serum inflammatory factors in patients with CVA to reduce inflammation and the allergic response, thereby reducing the cough symptom score, improving pulmonary function, and improving therapeutic efficacy. In addition, IL-6 and TGF-β 1 can be used as early predictors of budesonide inhalation efficacy. Keywords: budesonide, cough variant asthma, cytokines, IL-6, TGF-β 1 Cough variant asthma (CVA) is a type of asthma whose main clinical manifestation is chronic cough accompanied by airway hyperresponsiveness, with no obvious symptoms or signs of wheezing and shortness of breath, 1 and it is more obvious at night or in the early morning. In recent years, due to environmental changes, the overuse of antibiotics and other factors, the incidence of CVA has increased annually. 2,3 The pathogenesis of CVA has still not been fully elucidated. Scholars in China and abroad have proposed that CVA has certain similarities to typical bronchial asthma; that is, chronic inflammatory changes in the airway are predominantly caused by eosinophilic infiltration, with the participation of a variety of inflammatory cells and mediators, and airway hyperresponsiveness. 4,5 Moreover, eosinophils can produce leukotriene mediators, thus causing inflammation. 6 Moreover, simple and effective monitoring and evaluation measures for the treatment response and prognosis of patients with CVA are lacking. If CVA cannot be effectively controlled in a timely manner, it may develop into typical asthma. At present, the "Guidelines for the Diagnosis and Treatment of Cough" in China recommend glucocorticoids combined with conventional treatment for CVA, and the clinical benefits have been significant. Due to the differences between individual patients and variations in conditions, the treatment response of patients still needs to be evaluated in a timely manner during clinical treatment to rationally adjust regimens. 7 Routine treatments for CVA include bronchodilators, glucocorticoids, antiallergic drugs, and leukotriene receptor antagonists. 8,9 Budesonide is a glucocorticoid, and its unique molecular structure leads to long-acting, highly effective, and local anti-inflammatory effects. 10 It has a clear first-pass effect and can reduce inflammatory damage, control airway sensitivity, improve pulmonary function, and reduce the symptoms of asthma; therefore, it is often used in nebulized inhalation. 11 The commonly used clinical methods f -Abstract Truncated-

Modified Dingchuan Decoction treats cough-variant asthma by suppressing lung inflammation and regulating the lung microbiota

Mahuang Dingchuan Decoction improves airway inflammation in guinea pigs with cough variant asthma by regulating NLRP3 inflammasome

Therapeutic effects and mechanisms study of Hanchuan Zupa Granule in a Guinea pig model of cough variant asthma

Zi-Su-Zi decoction improves airway hyperresponsiveness in cough-variant asthma rat model through PI3K/AKT1/mTOR, JAK2/STAT3 and HIF-1α/NF-κB signaling pathways

β-Hydroxybutyric acid upregulated by Suhuang antitussive capsule ameliorates cough variant asthma through GSK3β/AMPK-Nrf2 signal axis

[Effect and mechanism of Maxing Shigan Decoction on reducing inflammatory response in rats with cough variant asthma via TLR4/MyD88/NF-κB and p38 MAPK signaling pathways]

Ethanol Extract of Anacyclus pyrethrum Root Ameliorates Cough-Variant Asthma Through the TLR4/NF-κB Pathway and Wnt/β-Catenin Pathway

Tuo-Min-Ding-Chuan Decoction Alleviate Ovalbumin-Induced Allergic Asthma by Inhibiting Mast Cell Degranulation and Down-Regulating the Differential Expression Proteins

Xiaoqinglong decoction suppresses childhood cough variant asthma and inhibited the body inflammatory response by regulating IL-6/STAT3 signalling pathway

Airway Inflammation, Bronchial Hyperresponsiveness, and Anti-Asthma Therapy Responses in Cough Variant Asthma and Classic Asthma with FEV1%≥80% Predicted

Combining metabolomics with network pharmacology to reveal the therapeutic mechanism of Dingchuan Decoction in rats with OVA-induced allergic asthma

Multi-omics analysis of lung tissue metabolome and proteome reveals the therapeutic effect of Shegan Mahuang Decoction against asthma in rats

The Protective Effects of Modified Dachaihu Decoction against LPS-induced Acute Lung Injury via Modulating PI3K/Akt Signalling Pathway

Treatment of Cough Due to Variant Asthma by Guangji Zhike Fang: A Clinical Observation of 30 Cases

Shegan-Mahuang decoction ameliorates cold-induced asthma via regulating the proliferation and apoptosis of airway smooth muscle cells through TAS2R10: An in vivo and in vitro study

Emodin Alleviates the Airway Inflammation of Cough Variant Asthma in Mice by Regulating the Notch Pathway

Mechanism of Jiawei Maxing Shigan Tang in treatment of acute exacerbated chronic obstructive pulmonary disease

LC-MS-based metabolomics reveals the in vivo effect of Shegan Mahuang Decoction in an OVA-induced rat model of airway hyperresponsiveness

The Effects of Budesonide Inhalation Treatment on the Expression Levels of Serum IL-6, TGF-β1, and IgE and Pulmonary Function in Patients with Cough Variant Asthma and an Evaluation of Treatment Efficacy

Water extract of Pingchuan formula ameliorated murine asthma through modulating metabolites and gut microbiota

Effects of Chuanxikang decoction on the amount of IFN-γand IL-5 in bronchoalveolar lavage fluid and expression of MMP-9 and TIMP-1 in lung tissue of asthmatic model in guinea Pig